Trial reportNeurogastroenterology and motility2014
Long-term efficacy of NASHA Dx injection therapy for treatment of fecal incontinence.
Trial report in Neurogastroenterology and motility, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Tools for fecal incontinence assessment: lessons for inflammatory bowel disease trials based on a systematic review.United European gastroenterology journal · 2020Pooled it
- Midterm outcomes of injectable bulking agents for fecal incontinence: a systematic review and meta-analysis.Techniques in coloproctology · 2017Pooled it
- The Japan Society of Coloproctology Practice Guidelines for Fecal Incontinence 2024 (Revised Second Edition).Journal of the anus, rectum and colon · 2026Review
- Injection of aluminum potassium sulfate and tannic acid in the treatment of fecal incontinence: a single-center observational study.Annals of coloproctology · 2022Article
- A short- and long-term follow-up study of intersphincteric NASHA Dx implants for fecal incontinence.Techniques in coloproctology · 2022Article
- An evaluation of the long-term effectiveness of Gatekeeper™ intersphincteric implants for passive faecal incontinence.Techniques in coloproctology · 2022Article
- Japanese Practice Guidelines for Fecal Incontinence Part 3 -Surgical Treatment for Fecal Incontinence, Fecal Incontinence in a Special Conditions- English Version.Journal of the anus, rectum and colon · 2021Review
- Constipation and Fecal Incontinence in the Elderly.Current gastroenterology reports · 2020Review
- The anatomy of Trans-Obturator Posterior Anal Sling (TOPAS) and dynamics of potential mechanism of action.Techniques in coloproctology · 2019Article
- Recent advances in managing fecal incontinence.F1000Research · 2019Review
- Outcomes of GatekeeperTechniques in coloproctology · 2017Observational
- Fecal Incontinence: Epidemiology, Impact, and Treatment.Clinics in colon and rectal surgery · 2016Article
- Current Trends in Management of Defecatory Dysfunction, Posterior Compartment Prolapse, and Fecal Incontinence.Current obstetrics and gynecology reports · 2016Article
- Functional Anorectal Disorders.Gastroenterology · 2016Article
- Evidence-Based Update on Treatments of Fecal Incontinence in Women.Obstetrics and gynecology clinics of North America · 2016Review
- Multicentre observational study of the Gatekeeper for faecal incontinence.The British journal of surgery · 2016Observational
- Treatment of fecal incontinence: state of the science summary for the National Institute of Diabetes and Digestive and Kidney Diseases workshop.The American journal of gastroenterology · 2015Article
- Management of pelvic floor disorders: biofeedback and more.Current treatment options in gastroenterology · 2014Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInjectable bulking treatment for fecal incontinence (FI) is intended to expand tissue in the anal canal and prevent fecal leakage. Use of injectable bulking agents is increasing because it can be performed in an outpatient setting and with low risk for morbidity. This study evaluated the long-term (36-month) clinical effectiveness and safety of injection of non-animal stabilized hyaluronic acid/dextranomer (NASHA Dx) on FI symptoms.
methodsIn a prospective multicenter trial, 136 patients with FI received the NASHA Dx bulking agent. Treatment success defined as a reduction in number of FI episodes by 50% or more compared with baseline (Responder50 ). Change from baseline in Cleveland Clinic Florida Fecal Incontinence Score (CCFIS) and Fecal Incontinence Quality of Life Scale (FIQL), and adverse events were also evaluated. KEY
resultsSuccessful decrease in symptoms was achieved in 52% of patients at 6 months and this was sustained at 12 months (57%) and 36 months (52%). Mean CCFIS decreased from 14 at baseline to 11 at 36 months (p < 0.001). Quality-of-life scores for all four domains improved significantly between baseline and 36 months of follow-up. Severe adverse events were rare and most adverse events were transient and pertained to minor bleeding and pain or discomfort. CONCLUSIONS & INFERENCES: Submucosal injection of NASHA Dx provided a significant improvement of FI symptoms in a majority of patients and this effect was stable during the course of the follow-up and maintained for 3 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.